The Company will continue its CR-AIR-008 trial, treating patients with a single dose of ATIR101TM according to the recommendation of the Independent Data Monitoring Committee and according to the clinical protocol. In this ongoing exploratory Phase II trial the safety and efficacy of a second dose of ATIR101TM is being tested in patients to investigate product flexibility in administering a further dose of ATIR101TM should it be needed by physicians.